First Trust RBA Deglobalization ETF (DGLO)
Live price chart, market sentiment, and community perspectives for First Trust RBA Deglobalization ETF (NASDAQ: DGLO).
Live price chart, market sentiment, and community perspectives for First Trust RBA Deglobalization ETF (NASDAQ: DGLO).
On our macro desk, the structural tailwind for DGLO is evident. Escalating U.S.-China trade friction and bipartisan reshoring legislation like the CHIPS Act and IRA are undeniably redirecting capital toward domestic industrials. However, with the portfolio heavily skewed toward industrials at nearly 62%, we have to weigh near-term earnings risk from tariff-induced cost inflation against the long-term thematic appeal.
Reviewing the liquidity profile of DGLO, I see major friction points. An expense ratio of 0.70% is far too steep compared to passive alternatives, and a ~0.17% bid-ask spread on just ~1,214 shares of daily volume makes executing larger blocks problematic. At only $2.24M in assets under management, the fund sits well below the threshold where closure risk becomes a serious structural concern.
From a technical standpoint, watching the 50-day moving average near 22.50 alongside a daily RSI around 51 gives a neutral read. Stochastic indicators have flashed short-term oversold conditions hinting at potential price bounces, but the broader lack of an extensive return history since its August 2025 launch makes standard backtesting impossible.
From a quantitative perspective, the fund's beta of 0.67 indicates attractive defensive market sensitivity relative to broad peers. Furthermore, the portfolio P/E of 17.12x offers a clear valuation discount against its index at 21.33x and category average at 19.98x, giving a modest cushion even if top-line growth decelerates globally.
Looking at recent institutional filings for Q2 2026, 7 hedge funds and large institutions hold about $1.96M in DGLO. We tracked 4 funds opening new positions and 2 increasing their holdings. While institutional accumulation is happening, the overall asset base remains exceptionally tiny for a broad market product.
Explore plasma cleansing, somatic organ swaps, and BCI.